KR101736416B1 - 고혈압 및/또는 섬유화 치료용 조성물 - Google Patents

고혈압 및/또는 섬유화 치료용 조성물 Download PDF

Info

Publication number
KR101736416B1
KR101736416B1 KR1020167008664A KR20167008664A KR101736416B1 KR 101736416 B1 KR101736416 B1 KR 101736416B1 KR 1020167008664 A KR1020167008664 A KR 1020167008664A KR 20167008664 A KR20167008664 A KR 20167008664A KR 101736416 B1 KR101736416 B1 KR 101736416B1
Authority
KR
South Korea
Prior art keywords
fibrosis
hypertension
compound
pmol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167008664A
Other languages
English (en)
Korean (ko)
Other versions
KR20160074471A (ko
Inventor
카렌 아넷 두간
Original Assignee
벡투스 바이오시스템즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903573A external-priority patent/AU2013903573A0/en
Application filed by 벡투스 바이오시스템즈 리미티드 filed Critical 벡투스 바이오시스템즈 리미티드
Publication of KR20160074471A publication Critical patent/KR20160074471A/ko
Application granted granted Critical
Publication of KR101736416B1 publication Critical patent/KR101736416B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167008664A 2013-09-17 2014-09-17 고혈압 및/또는 섬유화 치료용 조성물 Active KR101736416B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903573 2013-09-17
AU2013903573A AU2013903573A0 (en) 2013-09-17 Compositions for the treatment of hypertension and/or fibrosis
PCT/AU2014/000923 WO2015039173A1 (en) 2013-09-17 2014-09-17 Compositions for the treatment of hypertension and/or fibrosis

Publications (2)

Publication Number Publication Date
KR20160074471A KR20160074471A (ko) 2016-06-28
KR101736416B1 true KR101736416B1 (ko) 2017-05-16

Family

ID=52687998

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167008664A Active KR101736416B1 (ko) 2013-09-17 2014-09-17 고혈압 및/또는 섬유화 치료용 조성물

Country Status (22)

Country Link
US (1) US9458093B2 (enExample)
EP (1) EP3046901B1 (enExample)
JP (1) JP6122548B2 (enExample)
KR (1) KR101736416B1 (enExample)
CN (1) CN105683152B (enExample)
AP (1) AP2016009079A0 (enExample)
AU (1) AU2014324078B2 (enExample)
BR (1) BR112016005601B1 (enExample)
CA (1) CA2924356C (enExample)
DK (1) DK3046901T3 (enExample)
ES (1) ES2655455T3 (enExample)
IL (1) IL244621A (enExample)
MX (1) MX368865B (enExample)
MY (1) MY172557A (enExample)
NO (1) NO3046901T3 (enExample)
NZ (1) NZ717927A (enExample)
PH (1) PH12016500497B1 (enExample)
PL (1) PL3046901T3 (enExample)
RU (1) RU2635564C2 (enExample)
SG (1) SG11201601642WA (enExample)
UA (1) UA118111C2 (enExample)
WO (1) WO2015039173A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170129244A (ko) * 2015-03-18 2017-11-24 벡투스 바이오시스템즈 리미티드 섬유증 및 섬유증 관련 질병 치료용 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3284981B2 (ja) 1998-11-02 2002-05-27 株式会社デンソー 車両用交流発電機およびそのステータの製造方法
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
RU2712624C9 (ru) * 2015-03-18 2020-04-28 Вектус Байосистемс Лимитед Композиции для лечения заболевания почек и/или печени
EP3353147B1 (en) * 2015-09-22 2021-01-13 Vectus Biosystems Limited Synthesis of terphenyl compounds
KR102395342B1 (ko) * 2016-04-13 2022-05-10 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법
RU2747801C2 (ru) * 2016-07-28 2021-05-14 Вектус Байосистемс Лимитед Композиции для лечения легочного фиброза

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120545A1 (en) 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
US20110082109A1 (en) 2009-10-02 2011-04-07 Ajinomoto Co., Inc. Novel acyl guanidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694288B1 (fr) * 1992-06-30 1994-09-09 Rhone Poulenc Agrochimie Phenylbenzamides fongicides et procédés pour les préparer.
PT1976548E (pt) * 2005-12-09 2014-10-13 Vectus Biosystems Ltd Fragmentos de vip e suas composições
ES2694375T3 (es) * 2013-09-17 2018-12-20 Vectus Biosystems Limited Composiciones para el tratamiento de la hipertensión y/o de la fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120545A1 (en) 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
US20110082109A1 (en) 2009-10-02 2011-04-07 Ajinomoto Co., Inc. Novel acyl guanidine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170129244A (ko) * 2015-03-18 2017-11-24 벡투스 바이오시스템즈 리미티드 섬유증 및 섬유증 관련 질병 치료용 조성물
KR102591689B1 (ko) * 2015-03-18 2023-10-18 벡투스 바이오시스템즈 리미티드 섬유증 및 섬유증 관련 질병 치료용 조성물

Also Published As

Publication number Publication date
MX368865B (es) 2019-08-02
CA2924356A1 (en) 2015-03-26
UA118111C2 (uk) 2018-11-26
CN105683152A (zh) 2016-06-15
EP3046901A1 (en) 2016-07-27
DK3046901T3 (en) 2018-01-02
PH12016500497A1 (en) 2016-06-13
RU2016112257A (ru) 2017-10-20
EP3046901A4 (en) 2017-04-12
NZ717927A (en) 2018-12-21
EP3046901B1 (en) 2017-10-18
KR20160074471A (ko) 2016-06-28
WO2015039173A1 (en) 2015-03-26
RU2635564C2 (ru) 2017-11-14
CA2924356C (en) 2018-04-03
NO3046901T3 (enExample) 2018-03-17
MX2016003371A (es) 2016-10-21
BR112016005601B1 (pt) 2021-02-02
IL244621A (en) 2017-04-30
AU2014324078B2 (en) 2016-12-15
MY172557A (en) 2019-12-02
AU2014324078A1 (en) 2016-04-07
PH12016500497B1 (en) 2017-12-13
US20160221933A1 (en) 2016-08-04
PL3046901T3 (pl) 2018-03-30
BR112016005601A8 (pt) 2020-02-18
JP2016532632A (ja) 2016-10-20
SG11201601642WA (en) 2016-04-28
ES2655455T3 (es) 2018-02-20
AP2016009079A0 (en) 2016-03-31
JP6122548B2 (ja) 2017-04-26
US9458093B2 (en) 2016-10-04
CN105683152B (zh) 2017-03-22
IL244621A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
KR101736416B1 (ko) 고혈압 및/또는 섬유화 치료용 조성물
TWI689490B (zh) 用於治療纖維化之經取代之芳族化合物及相關方法
TWI848911B (zh) 以三唑并吡啶治療rbp4相關疾病之方法
US8119839B2 (en) Carboxylic acid and antidepressant composition containing the same as active ingredient
AU2014324075B2 (en) Compositions for the treatment of hypertension and/or fibrosis
US20180282287A1 (en) Azolylacryloyl derivatives as therapeutic agents for sickle cell disease
TW201544108A (zh) 異喹啉生物鹼衍生物用於製備促進ａｍｐｋ活性的藥物之用途
CN106866652A (zh) 具有胰岛素增敏活性的小檗碱12‑位衍生物及其制备方法
CN113402414A (zh) 一种苯甲酸衍生物及其制法和药物用途
US20210346331A1 (en) Trpv4 activity inhibitor
KR100903974B1 (ko) 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
HK1226324B (en) Compositions for the treatment of hypertension and/or fibrosis
HK1226324A1 (en) Compositions for the treatment of hypertension and/or fibrosis
US10183908B2 (en) Compositions for the treatment of kidney and/or liver disease
JPWO2014030624A1 (ja) スチルベン誘導体を有効成分として含有する筋緊張性ジストロフィー治療剤
KR101051077B1 (ko) 2-피페라지노-4,5-이중치환-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제
KR20100064953A (ko) 염증관련 질환치료제용 2,4-이중치환-5-아미노카르보닐-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제
JP2019089720A (ja) 化合物又はその薬学的に許容され得る塩、筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
CN103910718A (zh) 双环取代的吡唑酮偶氮类化合物、其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9